For colorectal and endometrial carcinomas, there is a trend towards universal screening for LS using MMR immunochemistry regardless of the patient age at diagnosis or family history [20, 21], because MMR immunolabeling can be performed on paraffin-embedded tissue sections, is inexpensive, and yields rapid results. The gene discussed is MRC1; the disease is endometrial carcinoma.